多粘菌素B在肾细胞中的摄取。
Uptake of polymyxin B into renal cells.
作者信息
Abdelraouf Kamilia, Chang Kai-Tai, Yin Taijun, Hu Ming, Tam Vincent H
机构信息
Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, Texas, USA.
Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2014 Jul;58(7):4200-2. doi: 10.1128/AAC.02557-14. Epub 2014 Apr 14.
Abstract
Polymyxin B is increasingly used as a treatment of last resort against multidrug-resistant Gram-negative infections. Using a mammalian kidney cell line, we demonstrated that polymyxin B uptake into proximal tubular epithelial cells was saturable and occurred primarily through the apical membrane, suggesting the involvement of transporters in the renal uptake of polymyxin B. Megalin might play a role in the uptake and accumulation of polymyxin B into renal cells.
摘要
多粘菌素B越来越多地被用作治疗多重耐药革兰氏阴性菌感染的最后手段。我们使用一种哺乳动物肾细胞系证明，多粘菌素B进入近端肾小管上皮细胞的过程是可饱和的，且主要通过顶膜发生，这表明转运体参与了多粘菌素B的肾脏摄取过程。巨膜蛋白可能在多粘菌素B摄取并积聚到肾细胞的过程中发挥作用。
相似文献
1
Uptake of polymyxin B into renal cells.多粘菌素B在肾细胞中的摄取。
Antimicrob Agents Chemother. 2014 Jul;58(7):4200-2. doi: 10.1128/AAC.02557-14. Epub 2014 Apr 14.
2
Measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?测量肾小管细胞对多粘菌素的摄取：BODIPY-多粘菌素B是合适的探针吗？
Antimicrob Agents Chemother. 2014 Oct;58(10):6337-8. doi: 10.1128/AAC.03733-14.
3
Reply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?".对《测量肾小管细胞对多粘菌素的摄取：BODIPY-多粘菌素B是合适的探针吗？》的回复
Antimicrob Agents Chemother. 2014 Oct;58(10):6339. doi: 10.1128/AAC.03784-14.
4
Mechanisms of gelofusine protection in an in vitro model of polymyxin B-associated renal injury.凝胶浮菌素在多粘菌素 B 相关性肾损伤体外模型中的保护机制。
Am J Physiol Renal Physiol. 2024 Jul 1;327(1):F137-F145. doi: 10.1152/ajprenal.00029.2024. Epub 2024 May 23.
5
Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes.使用合理设计的荧光探针研究多粘菌素在肾小管细胞中的细胞摄取及定位
Antimicrob Agents Chemother. 2015 Dec;59(12):7489-96. doi: 10.1128/AAC.01216-15. Epub 2015 Sep 21.
6
Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.多粘菌素B：针对多重耐药革兰氏阴性菌的新策略。
Expert Opin Investig Drugs. 2008 May;17(5):661-8. doi: 10.1517/13543784.17.5.661.
7
Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.多黏菌素B联合疗法治疗多重耐药革兰阴性菌引起的呼吸道感染。
J Antimicrob Chemother. 2004 Aug;54(2):566-9. doi: 10.1093/jac/dkh369. Epub 2004 Jul 21.
8
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.多粘菌素B用于治疗多重耐药病原体：一项批判性综述。
J Antimicrob Chemother. 2007 Dec;60(6):1206-15. doi: 10.1093/jac/dkm357. Epub 2007 Sep 17.
9
Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.耐多药革兰氏阴性菌血症和尿路感染患者肠外使用多黏菌素B：一项回顾性病例系列研究
Ann Pharmacother. 2008 Sep;42(9):1177-87. doi: 10.1345/aph.1K346. Epub 2008 Jul 29.
10
Clinical Use of Polymyxin B.多黏菌素 B 的临床应用。
Adv Exp Med Biol. 2019;1145:197-218. doi: 10.1007/978-3-030-16373-0_14.
引用本文的文献
1
: Epidemiology and resistance evolution of an emerging zoonotic bacteria.一种新兴人畜共患病细菌的流行病学与耐药性演变
One Health. 2025 Jun 16;21:101098. doi: 10.1016/j.onehlt.2025.101098. eCollection 2025 Dec.
2
Evaluating nephrotoxicity reduction in a novel polymyxin B formulation: insights from a 3D kidney-on-a-chip model.评估新型多粘菌素 B 制剂的肾毒性降低作用：来自 3D 肾芯片模型的见解。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0021924. doi: 10.1128/aac.00219-24. Epub 2024 Sep 3.
3
Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin-induced nephrotoxicity.遗传易感性和早期治疗期间高暴露于黏菌素是黏菌素诱导的肾毒性的独立危险因素。
Clin Transl Sci. 2024 Mar;17(3):e13764. doi: 10.1111/cts.13764.
4
Recent Advances in the Development of Polymyxin Antibiotics: 2010-2023.近年来多黏菌素类抗生素的研究进展：2010-2023。
ACS Infect Dis. 2024 Apr 12;10(4):1056-1079. doi: 10.1021/acsinfecdis.3c00630. Epub 2024 Mar 12.
5
Interactions Between Antimicrobial Peptides and Targets Responsible for their Nephrotoxic Action: Molecular Dynamics Simulations.抗菌肽与其肾毒性作用靶点之间的相互作用：分子动力学模拟
Curr Drug Saf. 2024;19(3):342-349. doi: 10.2174/1574886318666230905100924.
6
Mid-dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients.中剂量间隔浓度对重症患者的多黏菌素 B 暴露和急性肾损伤很重要。
CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1911-1921. doi: 10.1002/psp4.13040. Epub 2023 Sep 17.
7
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids.合成及评价带有还原性不稳定双硫键连接脂质的多粘菌素。
J Med Chem. 2022 Dec 8;65(23):15878-15892. doi: 10.1021/acs.jmedchem.2c01528. Epub 2022 Nov 18.
8
Effect of Different Dosage Frequency of Polymyxin B on Rat Nephrotoxicity.多黏菌素 B 不同给药频次对大鼠肾毒性的影响。
Drug Des Devel Ther. 2021 Feb 16;15:611-616. doi: 10.2147/DDDT.S287332. eCollection 2021.
9
Emerging peptide antibiotics with therapeutic potential.具有治疗潜力的新型肽类抗生素。
Med Drug Discov. 2021 Mar;9:100078. doi: 10.1016/j.medidd.2020.100078. Epub 2020 Dec 30.
10
In vitro mechanistic studies on α-amanitin and its putative antidotes.α-鹅膏蕈碱及其潜在解毒剂的体外机制研究。
Arch Toxicol. 2020 Jun;94(6):2061-2078. doi: 10.1007/s00204-020-02718-1. Epub 2020 Mar 19.
本文引用的文献
1
Megalin contributes to kidney accumulation and nephrotoxicity of colistin.巨胞饮作用导致多黏菌素在肾脏蓄积并产生肾毒性。
Antimicrob Agents Chemother. 2013 Dec;57(12):6319-24. doi: 10.1128/AAC.00254-13. Epub 2013 Oct 7.
2
Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.与多黏菌素 B 相比，在三级医疗中心的危重症患者中，静脉注射黏菌素甲磺酸钠的急性肾损伤发生率更高。
Clin Infect Dis. 2013 Nov;57(9):1300-3. doi: 10.1093/cid/cit453. Epub 2013 Jul 9.
3
A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies.一种经验证的超高效液相色谱-串联质谱法，用于定量检测小鼠血清和上皮衬液中的多粘菌素 B：在药代动力学研究中的应用。
J Antimicrob Chemother. 2013 May;68(5):1104-10. doi: 10.1093/jac/dks536. Epub 2013 Jan 22.
4
Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats: insight from the nmr structure of the 10th complement type repeat domain alone and in complex with gentamicin.庆大霉素通过补体类型重复的常见配体结合基序作为竞争性抑制剂与巨球蛋白受体结合：来自单独的第 10 个补体类型重复结构域及其与庆大霉素复合物的 NMR 结构的见解。
J Biol Chem. 2013 Feb 8;288(6):4424-35. doi: 10.1074/jbc.M112.434159. Epub 2012 Dec 27.
5
Pharmacokinetics and renal disposition of polymyxin B in an animal model.多粘菌素 B 在动物模型中的药代动力学和肾处置。
Antimicrob Agents Chemother. 2012 Nov;56(11):5724-7. doi: 10.1128/AAC.01333-12. Epub 2012 Aug 20.
6
Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.多粘菌素 B 诱导的肾毒性的特征：对给药方案设计的影响。
Antimicrob Agents Chemother. 2012 Sep;56(9):4625-9. doi: 10.1128/AAC.00280-12. Epub 2012 Jun 11.
7
Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy.静脉注射多黏菌素 B 治疗相关急性肾损伤的发生率及预测因素。
J Infect. 2012 Jul;65(1):80-7. doi: 10.1016/j.jinf.2012.01.015. Epub 2012 Feb 2.
8
Variability of polymyxin B major components in commercial formulations.市售制剂中多粘菌素B主要成分的变异性。
Int J Antimicrob Agents. 2010 Mar;35(3):308-10. doi: 10.1016/j.ijantimicag.2009.11.005. Epub 2009 Dec 31.
9
In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa.多粘菌素B对产IMP型金属β-内酰胺酶的铜绿假单胞菌的体外和体内抗菌效力
Int J Antimicrob Agents. 2008 Nov;32(5):437-40. doi: 10.1016/j.ijantimicag.2008.05.006. Epub 2008 Aug 19.
10
Clinical and economic impact of common multidrug-resistant gram-negative bacilli.常见多重耐药革兰氏阴性杆菌的临床和经济影响
Antimicrob Agents Chemother. 2008 Mar;52(3):813-21. doi: 10.1128/AAC.01169-07. Epub 2007 Dec 10.
Zotero 插件